A Single-arm Phase II Clinical Study of Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Patients With Advanced Pancreatic Cancer
Latest Information Update: 21 May 2025
At a glance
- Drugs Cadonilimab (Primary) ; Capecitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Therapeutic Use
Most Recent Events
- 14 May 2025 Status changed from not yet recruiting to recruiting.
- 06 Aug 2024 New trial record